John Smither

Mr. John W.
Smither, CPA, is a Chief Financial Officer at MBX Biosciences, Inc., an Independent Director at Genelux Corp., an Independent Non-Executive Director at NewAmsterdam Pharma Co. NV, a Member at California Society of Certified Public Accountants, a Member at Financial Executives International and a Member at The American Institute of Certified Public Accountants.
He is on the Board of Directors at Genelux Corp., NewAmsterdam Pharma Co. NV and eFFECTOR Therapeutics Operations, Inc. Mr. Smither was previously employed as a Chief Financial Officer by Arcutis Biotherapeutics, Inc., an Independent Director by Applied Molecular Transport, Inc., a Chief Financial Officer by Arcutis Biotherapeutics, Inc., an Independent Director by Principia Biopharma, Inc., a Chief Financial Officer by Sienna Biopharmaceuticals, Inc., an Independent Director by eFFECTOR Therapeutics, Inc., a Chief Financial Officer by Kite Pharma, Inc., a Chief Financial Officer by Sienna Biopharmaceuticals, Inc., a Chief Financial Officer by Unity Biotechnology, Inc., an Independent Director by Achaogen, Inc., a Chief Financial Officer by Kythera Biopharmaceuticals Inc, a Chief Financial Officer by Amgen Europe BV, a Vice President-Finance & Administration by Amgen, Inc., and an Audit Partner by Ernst & Young LLP (Missouri).
He also served on the board at Dompe Biotec SpA. He received his undergraduate degree from California State University-Los Angeles.